Clinical trial
Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With…
NCT02629393 · Origin Biosciences, Industry · Completed
Key facts
| NCT number | NCT02629393 |
|---|---|
| Title | Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A |
| Official title | A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A |
| Lead sponsor | Origin Biosciences, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Molybdenum Cofactor Deficiency, Type A |
| Intervention type | Drug |
| Interventions | ORGN001 (formerly ALXN1101) |
| Enrollment | 5 |
| Start date | May 1, 2016 |
| Primary completion | Sep 1, 2022 |
| Completion | Oct 1, 2022 |
| First posted | Dec 14, 2015 |
| Last update posted | Oct 17, 2023 |
| Countries | Israel, Norway, Spain, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: